Shane Schaffer, Cingulate Chairman & CEO to Present “SMART Launch” Approach at Indegene Digital Summit: Rethinking Commercialization for Emerging Pharma
Stocks in this Quantisnow insightHealth Care
Historical context for CING
Across the 13 sessions after earlier CING headlines, the stock closed higher 3 times and lower 10 times, with a median move of 5.2% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | CING | SPY |
|---|---|---|---|
| Aug 13, 2026 | Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness | -4.2% | +0.7% |
| Aug 11, 2026 | Cingulate Publishes Peer-Reviewed Data Demonstrating CTx-1301’s Differentiated Pharmacokinetic Profile | -1.0% | -0.3% |
| Jul 30, 2026 | Cingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent Psychopharmacology | +5.2% | +1.7% |
| Jul 2, 2026 | Cingulate Inc. (NASDAQ: CING) Added to Russell 3000E® | -8.7% | -0.1% |
| Jun 16, 2026 | Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301 | -3.9% | -0.6% |
| Jun 2, 2026 | Cingulate Receives Complete Response Letter from FDA for CTx-1301 | +11.9% | +0.1% |
Quantisnow market dataNASDAQ
CING
Cingulate Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2021
Get push alerts for CING
Full CING profile on Quantisnow Follow CING and get a push notification the moment its next story breaks.